ASCVD Risk Reduction in Patients with Immune-Mediated Inflammatory Disease: A Retrospective Quality Assessment Study

IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Nasser Monzer MD, Emma MacAllister CRNP, Archna Bajaj MD, Daniel Soffer MD, Douglas Jacoby MD, Srinivas Denduluri PhD, Deepak Vedamurthy MD
{"title":"ASCVD Risk Reduction in Patients with Immune-Mediated Inflammatory Disease: A Retrospective Quality Assessment Study","authors":"Nasser Monzer MD,&nbsp;Emma MacAllister CRNP,&nbsp;Archna Bajaj MD,&nbsp;Daniel Soffer MD,&nbsp;Douglas Jacoby MD,&nbsp;Srinivas Denduluri PhD,&nbsp;Deepak Vedamurthy MD","doi":"10.1016/j.jacl.2024.04.039","DOIUrl":null,"url":null,"abstract":"<div><h3>Background/Synopsis</h3><p>Patients with inflammatory immune-mediated disease (IMID) face a heightened risk of atherosclerotic cardiovascular disease (ASCVD). Current guidelines (2018, Grundy et al.) suggest considering a moderate-intensity statin for primary prevention if the 10-year ASCVD risk exceeds 5% in the presence of risk enhancers like IMID (Class IIb recommendation). However, many patients with IMID are undertreated with lipid-lowering therapies (LLT) as traditional ASCVD risk calculators often overlook this enhanced ASCVD risk. The 2022 ACC Expert Consensus decision pathway recommends a target LDL-C of at least 100 mg/dL and preferably less than 70 mg/dL for higher-risk patients for primary prevention. An LDL-C of less than 55 mg/dL is optimal for secondary ASCVD prevention.</p></div><div><h3>Objective/Purpose</h3><p>Identify the proportion of patients with IMID at our institution who meet criteria to start LLT (defined as ASCVD risk greater than 5% in the presence of risk enhancers or history of clinical ASCVD), proportion of such patients who are prescribed LLT, and the proportion of patients who meet goal LDL-C for primary and secondary prevention of ASCVD. Additionally, we sought to identify what proportion of those patients underwent coronary artery calcium scoring (CACS) and/or measurement of carotid intima-media thickness (CIMT) to guide decision-making in ASCVD risk management.</p></div><div><h3>Methods</h3><p>This is a retrospective quality assessment study using data from the Penn Medicine electronic medical records. Patients between 40 and 75 years of age, attending Rheumatology and Dermatology clinics during the calendar year 2022, with the following diagnoses were included: psoriasis, rheumatoid arthritis, systemic lupus erythematosus, gout, vasculitis, systemic sclerosis, antiphospholipid syndrome, mixed connective tissue disease, myositis. Patients with missing covariates to calculate the ASCVD risk score and study outcomes were excluded.</p></div><div><h3>Results</h3><p>1,907 patients were identified, 29% of which had clinical ASCVD. 69% (1,321) were eligible for LLT. 53% (702) of eligible patients were prescribed LLT, while 47% were not. Among patients who met criteria for LLT, 58% had their most recent LDL-C under 100 mg/dL, while 33% had their most recent LDL-C less than 70 mg/dL. 16% of patients with clinical ASCVD had their most recent LDL-C level less than 55 mg/dL. CACS or CIMT was performed on 10% of our cohort.</p></div><div><h3>Conclusions</h3><p>This study supports our hypothesis that ASCVD risk management in patients with IMID is suboptimal. With advances in subclinical atherosclerosis imaging and newer non-statin therapies, there is potential to improve cardiovascular outcomes in patients with IMID. Further studies are needed to bridge the management gaps in this patient population.</p></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"18 4","pages":"Pages e510-e511"},"PeriodicalIF":3.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical lipidology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1933287424000862","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background/Synopsis

Patients with inflammatory immune-mediated disease (IMID) face a heightened risk of atherosclerotic cardiovascular disease (ASCVD). Current guidelines (2018, Grundy et al.) suggest considering a moderate-intensity statin for primary prevention if the 10-year ASCVD risk exceeds 5% in the presence of risk enhancers like IMID (Class IIb recommendation). However, many patients with IMID are undertreated with lipid-lowering therapies (LLT) as traditional ASCVD risk calculators often overlook this enhanced ASCVD risk. The 2022 ACC Expert Consensus decision pathway recommends a target LDL-C of at least 100 mg/dL and preferably less than 70 mg/dL for higher-risk patients for primary prevention. An LDL-C of less than 55 mg/dL is optimal for secondary ASCVD prevention.

Objective/Purpose

Identify the proportion of patients with IMID at our institution who meet criteria to start LLT (defined as ASCVD risk greater than 5% in the presence of risk enhancers or history of clinical ASCVD), proportion of such patients who are prescribed LLT, and the proportion of patients who meet goal LDL-C for primary and secondary prevention of ASCVD. Additionally, we sought to identify what proportion of those patients underwent coronary artery calcium scoring (CACS) and/or measurement of carotid intima-media thickness (CIMT) to guide decision-making in ASCVD risk management.

Methods

This is a retrospective quality assessment study using data from the Penn Medicine electronic medical records. Patients between 40 and 75 years of age, attending Rheumatology and Dermatology clinics during the calendar year 2022, with the following diagnoses were included: psoriasis, rheumatoid arthritis, systemic lupus erythematosus, gout, vasculitis, systemic sclerosis, antiphospholipid syndrome, mixed connective tissue disease, myositis. Patients with missing covariates to calculate the ASCVD risk score and study outcomes were excluded.

Results

1,907 patients were identified, 29% of which had clinical ASCVD. 69% (1,321) were eligible for LLT. 53% (702) of eligible patients were prescribed LLT, while 47% were not. Among patients who met criteria for LLT, 58% had their most recent LDL-C under 100 mg/dL, while 33% had their most recent LDL-C less than 70 mg/dL. 16% of patients with clinical ASCVD had their most recent LDL-C level less than 55 mg/dL. CACS or CIMT was performed on 10% of our cohort.

Conclusions

This study supports our hypothesis that ASCVD risk management in patients with IMID is suboptimal. With advances in subclinical atherosclerosis imaging and newer non-statin therapies, there is potential to improve cardiovascular outcomes in patients with IMID. Further studies are needed to bridge the management gaps in this patient population.

降低免疫性炎症性疾病患者的 ASCVD 风险:一项回顾性质量评估研究
背景/简介炎症性免疫介导疾病(IMID)患者面临着更高的动脉粥样硬化性心血管疾病(ASCVD)风险。现行指南(2018 年,Grundy 等人)建议,如果存在 IMID 等风险增强因素,10 年 ASCVD 风险超过 5%,则考虑使用中等强度他汀类药物进行一级预防(IIb 类推荐)。然而,由于传统的 ASCVD 风险计算器通常会忽略这种增强的 ASCVD 风险,因此许多 IMID 患者的降脂疗法(LLT)治疗不足。2022 年 ACC 专家共识决策路径建议,高风险患者的一级预防目标 LDL-C 至少为 100 mg/dL,最好低于 70 mg/dL。目标/目的确定本机构符合开始 LLT 标准的 IMID 患者比例(定义为存在风险增强剂或临床 ASCVD 病史的 ASCVD 风险大于 5%)、开具 LLT 处方的此类患者比例以及达到 ASCVD 一级和二级预防目标 LDL-C 的患者比例。此外,我们还试图确定这些患者中接受冠状动脉钙化评分(CACS)和/或颈动脉内膜中层厚度(CIMT)测量以指导 ASCVD 风险管理决策的比例。研究对象包括在 2022 年期间在风湿病学和皮肤病学门诊就诊的 40 至 75 岁患者,他们的诊断如下:银屑病、类风湿性关节炎、系统性红斑狼疮、痛风、血管炎、系统性硬化症、抗磷脂综合征、混合结缔组织病、肌炎。计算 ASCVD 风险评分和研究结果的协变量缺失的患者被排除在外。69%的患者(1,321人)符合接受LLT治疗的条件。在符合条件的患者中,53%(702人)获得了LLT处方,47%未获处方。在符合 LLT 标准的患者中,58% 最近的 LDL-C 低于 100 mg/dL,33% 最近的 LDL-C 低于 70 mg/dL。16%的临床 ASCVD 患者最近的 LDL-C 水平低于 55 mg/dL。结论这项研究支持了我们的假设,即 IMID 患者的 ASCVD 风险管理并不理想。随着亚临床动脉粥样硬化成像技术和新型非他汀类药物疗法的发展,IMID 患者的心血管预后有望得到改善。还需要进一步的研究来弥补这一患者群体在管理方面的不足。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.00
自引率
6.80%
发文量
209
审稿时长
49 days
期刊介绍: Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信